Fda approves nivolumab plus ipilimumab for first-line metastatic non-small cell lung cancer

Fda - approves bristol-myers squibb' nivolumab plus ipilimumab for first-line metastatic non-small cell lung cancer (pd-l1 tumor expression ≥1%).fda - approved pd-l1 ihc 28-8 pharmdx as a companion diagnostic device for selecting patients with nsclc for treatment with nivolumab plus ipilimumab.
A Ratings Summary
A Quant Ranking